Enzymatic vitreous surgery

Seminars in Ophthalmology

Volumn 15, Issue 2, 2000, Pages 116-121

  Trese, Michael T ^a,b,c,d  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d 632 William Beaumont Med Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VITRECTOMY; VITREORETINOPATHY;

EID: 0034095773     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820530009040002     Document Type: Article

References (17)

1. Cleary PE, Ryan SJ. Vitrectomy in penetrating eye injury; Results of a controlled trial of vitrectomy in an experimental posterior penetrating eye injury in the rhesus monkey. Arch Ophthalmol. 1981;99:287-292.
2. de Juan E, Sternberg P, Michels RG. Evaluation of vitrectomy in a penetrating ocular trauma: A case control study. Arch Ophthalmol. 1984;102:1160-1163.
3. Verstraeten TC, Chapman C, Hartzer M, et al. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol. 1993;111:849-854.
4. Trese MT, Williams GA, Hartzer M. Autologous plasmin enzyme-assisted vitreous surgery. Presented at the Retina Society, Berne, Switzerland, 1996.
5. Williams GA. Discussion of visual field defects after macular hole surgery. Ophthalmology. 1996;103:2158-2159.
6. Hutton WI, Fuller DG, Snyder WB, et al. Visual field defects after macular hole surgery. Ophthalmology. 1996; 103:2157-2159.
7. Pendergast SD, Hartzer M, Dailey W, et al. Fluid-gas exchange following intravitreal plasmin injection in a rabbit model. Invest Ophthalmol Vis Sci. 1996;37(suppl):913.
8. Williams GA, Lambrou FH, Jaffe GJ, et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 1988;106:1055-1088.
9. Peyman GA, Nelson NC, Alturki W, et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmol Surg. 1991;11:575-582.
10. Johnson MW, Olsen KL, Hernandez E. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina. 1991;11:250-255.
11. Lewis H, Resnick SC, Flannery JF, et al. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol. 1991;111:197-204.
12. Irvine WD, Johnson MW, Hernandez E, et al. Retinal toxicity of human plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol. 1991;109:718-723.
13. Jaffe GH, Green DJG, McKay BS, et al. Intravitreal clearance of tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1991;106:969-973.
14. Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic retinopathy. Gerlair J Ophthalmol. 1995;4:323-327.
15. Russell SR, Shepard JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membranes. Invest Ophthalmol Vis Sci. 1991;32:1986-1995.
16. Russell SR, Kincaid MC, Hageman GS. Pathological consequences of mechanically-induced posterior vitreous detachment. Invest Ophthalmol Vis Sci. 1996;37(suppl):2267.
17. Hageman GS, Russell SR. Chondroitinate-mediated disinsertion of the primate vitreous body. Invest Ophthalmol Vis Sci. 1994;35(suppl):28.